Pediatric Clostridium difficile: a phantom menace or clinical reality?
McFarland
L V
LV
Department of Medicinal Chemistry, University of Washington, Seattle, USA. lvmcfarl@u.washington.edu
Brandmarker
S A
SA
Guandalini
S
S
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D002648:Child; D002675:Child, Preschool; D016360:Clostridioides difficile / Q000254:growth & development / Q000302:isolation & purification*; D003428:Cross Infection / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy; D003603:Cytotoxins / Q000096:biosynthesis; D003967:Diarrhea; D004196:Disease Outbreaks / Q000517:prevention & control; D004761:Enterocolitis, Pseudomembranous / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy; D005260:Female; D006801:Humans; D015994:Incidence; D007223:Infant; D008297:Male; D015995:Prevalence; D012307:Risk Factors
D003603:Cytotoxins